Biomica
Biomica is a clinical-stage biopharmaceutical company dedicated to developing innovative microbiome-based therapeutics for the treatment of cancer, immune-mediated, and infectious diseases. Leveraging proprietary big data and computational capabilities, Biomica aims to address high-value, unmet medical needs with best-in-class therapeutics.
Industries
Nr. of Employees
small (1-50)
Biomica
13 Gad Feinstein st. Park Rehovot, Israel
Products
BMC-128
A rationally designed live bacterial consortium (multi-strain LBP) developed for use in combination with immune checkpoint inhibitor therapy to enhance anti-tumor immune responses; progressed to a first-in-human Phase I proof-of-concept study.
BMC321 & BMC322
Rationally designed live bacterial consortia intended to reduce gut mucosal inflammation; evaluated in preclinical studies for inflammatory bowel disease indications.
BMC333
Optimized live bacterial product comprising four strains selected for complementary functional activities; demonstrated preclinical efficacy in a DSS-induced colitis animal model and planned for scale-up toward clinical batch production.
BMC-128
A rationally designed live bacterial consortium (multi-strain LBP) developed for use in combination with immune checkpoint inhibitor therapy to enhance anti-tumor immune responses; progressed to a first-in-human Phase I proof-of-concept study.
BMC321 & BMC322
Rationally designed live bacterial consortia intended to reduce gut mucosal inflammation; evaluated in preclinical studies for inflammatory bowel disease indications.
BMC333
Optimized live bacterial product comprising four strains selected for complementary functional activities; demonstrated preclinical efficacy in a DSS-induced colitis animal model and planned for scale-up toward clinical batch production.
Services
Joint clinical research agreements with medical centers to perform deep sequencing, high-resolution microbiome analysis and translational studies aimed at identifying therapeutic entities and biomarkers.
In-house computational analysis service using AI-driven platforms to prioritize microbial strains, functions and consortia for therapeutic development in microbiome-related indications.
Joint clinical research agreements with medical centers to perform deep sequencing, high-resolution microbiome analysis and translational studies aimed at identifying therapeutic entities and biomarkers.
In-house computational analysis service using AI-driven platforms to prioritize microbial strains, functions and consortia for therapeutic development in microbiome-related indications.
Expertise Areas
- Microbiome-based therapeutics
- Immuno-oncology
- Gastrointestinal disease (IBD) therapeutics
- Antimicrobial resistance therapeutics
Key Technologies
- Computational predictive biology platform
- AI and Big Data analytics for biology
- Metagenomic sequencing
- High-resolution taxonomic and functional microbiome profiling
News & Updates
Biomica’s CEO, Dr. Elran Haber, is heading to Brussels for the Microbiome Times Partnering Forum, a key event for advancing microbiome-based therapeutics through strategic partnerships.
Dr. Elran Haber, Biomica’s CEO, will attend MIXiii Health-Tech.IL 2025 at ICC Jerusalem, exploring innovations in personalized medicine, AI-driven drug development, and cancer treatment.
Biomica’s CEO, Dr. Elran Haber, will represent the company on the U.S. delegation organized by Startup Nation Central.
Professor Gal Markel, an expert in tumor immunology and clinical immuno-oncology, joins Biomica’s Scientific Advisory Board to support its immuno-oncology clinical development program.
Biomica’s CEO, Dr. Elran Haber, is heading to Brussels for the Microbiome Times Partnering Forum, a key event for advancing microbiome-based therapeutics through strategic partnerships.
Dr. Elran Haber, Biomica’s CEO, will attend MIXiii Health-Tech.IL 2025 at ICC Jerusalem, exploring innovations in personalized medicine, AI-driven drug development, and cancer treatment.
Biomica’s CEO, Dr. Elran Haber, will represent the company on the U.S. delegation organized by Startup Nation Central.
Professor Gal Markel, an expert in tumor immunology and clinical immuno-oncology, joins Biomica’s Scientific Advisory Board to support its immuno-oncology clinical development program.